These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11303477)

  • 21. PSA scores: should we use a lower threshold?
    Carter HB
    Johns Hopkins Med Lett Health After 50; 2004 Oct; 17(8):6. PubMed ID: 15602780
    [No Abstract]   [Full Text] [Related]  

  • 22. [Vascular endothelial growth factor and insulin-like-growth factors in prostate cancer. ].
    Trapeznikova MF; Shibaeva AN; Ianshin AA; Urenkov SB; Mironova OS; Kazantseva IA; Kushlinskiĭ NE
    Urologiia; 2004; (1):17-21. PubMed ID: 15022438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: a prospective multiethnic study.
    Borugian MJ; Spinelli JJ; Sun Z; Kolonel LN; Oakley-Girvan I; Pollak MD; Whittemore AS; Wu AH; Gallagher RP
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):252-4. PubMed ID: 18199733
    [No Abstract]   [Full Text] [Related]  

  • 24. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.
    Chen C; Lewis SK; Voigt L; Fitzpatrick A; Plymate SR; Weiss NS
    Cancer; 2005 Jan; 103(1):76-84. PubMed ID: 15540247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.
    Severi G; Morris HA; MacInnis RJ; English DR; Tilley WD; Hopper JL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1137-41. PubMed ID: 16775172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current issues and reported findings from the National Survey on Benign Prostatic Hyperplasia.
    Fawzy A
    Int J Clin Pract Suppl; 2001 Sep; (122):2-22. PubMed ID: 11695085
    [No Abstract]   [Full Text] [Related]  

  • 27. A more accurate prostate test?
    Health News; 2001 Jan; 7(1):6. PubMed ID: 11198413
    [No Abstract]   [Full Text] [Related]  

  • 28. [Diagnostic value of complexed prostate-specific antigen for prostate cancer].
    Su HW; Li Y; Xu P
    Zhonghua Nan Ke Xue; 2003 Sep; 9(6):431-3. PubMed ID: 14574807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
    Filella X; Alcover J; Corral JM; Molina R; Beardo P; Ballesta AM
    Anticancer Res; 2001; 21(5):3717-20. PubMed ID: 11848550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostatic-specific antigen velocity after holmium laser enucleation of the prostate: possible predictor for the assessment of treatment effect durability for benign prostatic hyperplasia and detection of malignancy.
    Elmansy HM; Elzayat EA; Sampalis JS; Elhilali MM
    Urology; 2009 Nov; 74(5):1105-10. PubMed ID: 19773035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
    Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
    Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
    Serdar MA; Oguz O; Olgun A; Seçkin B; Ilgan S; Hasimi A; Salih M; Peker F; Kutluay T
    Ann Clin Lab Sci; 2002; 32(1):22-30. PubMed ID: 11848613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer.
    Romppanen J; Haapalainen T; Punnonen K; Penttilä I
    Anticancer Res; 2002; 22(1A):415-20. PubMed ID: 12017325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
    Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
    J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
    Andriole GL; Marberger M; Roehrborn CG
    J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prostate specific antigen and diagnosis of prostate cancer].
    Rigaud J; Bouchot O
    Rev Prat; 2003 Dec; 53(20):2229-36. PubMed ID: 15018076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer screening.
    Stattin P; Stenman UH; Riboli E; Hallmans G; Kaaks R
    Lancet; 2001 Apr; 357(9263):1202-3. PubMed ID: 11332426
    [No Abstract]   [Full Text] [Related]  

  • 38. Pro PSA : a "pro cancer" form of PSA?
    Peyromaure M; Fulla Y; Debré B; Dinh-Xuan AT
    Med Hypotheses; 2005; 64(1):92-5. PubMed ID: 15533620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer.
    de Vries SH; Raaijmakers R; Blijenberg BG; Mikolajczyk SD; Rittenhouse HG; Schröder FH
    Urology; 2005 May; 65(5):926-30. PubMed ID: 15882725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening?
    Wolk A; Andersson SO; Mantzoros CS; Trichopoulos D; Adami HO
    Lancet; 2000 Dec; 356(9245):1902-3. PubMed ID: 11130391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.